These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38279671)

  • 1. Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study.
    Chen PY; Chiu CC; Chang CK; Lu ML; Huang CY; Chen CH; Huang MC
    J Psychopharmacol; 2024 Mar; 38(3):258-267. PubMed ID: 38279671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orexin-a elevation in antipsychotic-treated compared to drug-free patients with schizophrenia: A medication effect independent of metabolic syndrome.
    Chen PY; Chang CK; Chen CH; Fang SC; Mondelli V; Chiu CC; Lu ML; Hwang LL; Huang MC
    J Formos Med Assoc; 2022 Nov; 121(11):2172-2181. PubMed ID: 35396156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.
    Semiz UB; Cetin M; Basoglu C; Ebrinc S; Uzun O; Herken H; Balibey H; Algul A; Ates A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1330-6. PubMed ID: 17618026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical predictors of response to clozapine in Tunisian patients with treatment resistant schizophrenia.
    Aissa A; Jouini R; Ouali U; Zgueb Y; Nacef F; El Hechmi Z
    Compr Psychiatry; 2022 Jan; 112():152280. PubMed ID: 34763293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study.
    Bioque M; Parellada E; García-Rizo C; Amoretti S; Fortea A; Oriolo G; Palau P; Boix-Quintana E; Safont G; Bernardo M
    Eur Psychiatry; 2020 Jul; 63(1):e71. PubMed ID: 32669145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics.
    Chen PY; Chen CH; Chang CK; Kao CF; Lu ML; Lin SK; Huang MC; Hwang LL; Mondelli V
    Int J Neuropsychopharmacol; 2019 Jan; 22(1):28-36. PubMed ID: 30204875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Orexin-A and brain-derived neurotrophic factor levels in metabolic syndrome and cognitive impairment in schizophrenia treated with clozapine.
    Ren J; Chen Y; Fang X; Wang D; Wang Y; Yu L; Wu Z; Liu R; Zhang C
    Neurosci Lett; 2022 Jun; 782():136695. PubMed ID: 35618081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal course of cognition in schizophrenia: Does treatment resistance play a role?
    Spangaro M; Martini F; Bechi M; Buonocore M; Agostoni G; Cocchi F; Sapienza J; Bosia M; Cavallaro R
    J Psychiatr Res; 2021 Sep; 141():346-352. PubMed ID: 34304039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
    Barber S; Olotu U; Corsi M; Cipriani A
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006324. PubMed ID: 28333365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.
    de Bartolomeis A; Balletta R; Giordano S; Buonaguro EF; Latte G; Iasevoli F
    Psychiatry Res; 2013 Dec; 210(2):387-95. PubMed ID: 23910239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.
    Ciapparelli A; Dell'Osso L; Bandettini di Poggio A; Carmassi C; Cecconi D; Fenzi M; Chiavacci MC; Bottai M; Ramacciotti CE; Cassano GB
    J Clin Psychiatry; 2003 Apr; 64(4):451-8. PubMed ID: 12716249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial.
    Zhu MH; Liu ZJ; Hu QY; Yang JY; Jin Y; Zhu N; Huang Y; Shi DH; Liu MJ; Tan HY; Zhao L; Lv QY; Yi ZH; Wu FC; Li ZZ
    Mil Med Res; 2022 Oct; 9(1):59. PubMed ID: 36253804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
    Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
    Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
    J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A new therapeutic approach tp drug-resistant schizophrenia: clozapine. Long-term prospective study in 16 patients].
    Jalenques I; Coudert AJ
    Acta Psychiatr Belg; 1992; 92(6):323-38. PubMed ID: 1364281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia.
    Rajkumar AP; Poonkuzhali B; Kuruvilla A; Srivastava A; Jacob M; Jacob KS
    Psychopharmacology (Berl); 2012 Dec; 224(3):441-9. PubMed ID: 22700043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disorganization domain as a putative predictor of Treatment Resistant Schizophrenia (TRS) diagnosis: A machine learning approach.
    Barone A; De Prisco M; Altavilla B; Avagliano C; Balletta R; Buonaguro EF; Ciccarelli M; D'Ambrosio L; Giordano S; Latte G; Matrone M; Milandri F; Francesco DN; Vellucci L; de Bartolomeis A
    J Psychiatr Res; 2022 Nov; 155():572-578. PubMed ID: 36206601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Retrospective Investigation of Clozapine Treatment in Autistic and Nonautistic Children and Adolescents in an Inpatient Clinic in Turkey.
    Yalcin O; Kaymak G; Erdogan A; Tanidir C; Karacetin G; Kilicoglu AG; Mutlu C; Adaletli H; Gunes H; Bahali K; Ayik B; Uneri OS
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):815-821. PubMed ID: 26771824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic approaches for treatment-resistant schizophrenia: a look to the future.
    Miyamoto S; Jarskog LF; Fleischhacker WW
    J Psychiatr Res; 2014 Nov; 58():1-6. PubMed ID: 25070124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.